BC Extra | Apr 12, 2019
Financial News

Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ. Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous...
Items per page:
1 - 1 of 1